Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Liabilities and Shareholders Equity (2016 - 2026)

Iradimed has reported Liabilities and Shareholders Equity over the past 14 years, most recently at $114.4 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 12.44% to $114.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $444.3 million through Mar 2026, up 15.64% year-over-year, with the annual reading at $108.8 million for FY2025, 10.63% up from the prior year.
  • Liabilities and Shareholders Equity was $114.4 million for Q1 2026 at Iradimed, up from $108.8 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $114.7 million in Q3 2025 and troughed at $72.4 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $89.9 million (2024), against an average of $92.1 million.
  • Year-over-year, Liabilities and Shareholders Equity increased 0.19% in 2022 and then grew 21.72% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $85.5 million in 2022, then increased by 7.77% to $92.2 million in 2023, then rose by 6.7% to $98.3 million in 2024, then grew by 10.63% to $108.8 million in 2025, then rose by 5.16% to $114.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Liabilities and Shareholders Equity are $114.4 million (Q1 2026), $108.8 million (Q4 2025), and $114.7 million (Q3 2025).